GSK cancer immunotherapy receives backing from key EMA committee
Proactive Investors
Published Oct 16, 2023 08:50
Updated Oct 16, 2023 09:10
GSK cancer immunotherapy receives backing from key EMA committee
Proactive Investors - GSK PLC (LON:GSK) said its cancer immunotherapy drug, Jemperli (dostarlimab), has been recommended for approval by a key committee at the European Medicines Agency.
Specifically, regulators have endorsed its use in combination with chemotherapy treatments to tackle primary advanced or recurrent endometrial cancer.
The opinion of the Committee for Medicinal Products for Human Use was based on results from the RUBY phase III trial, which showed a 72% reduction in the risk of disease progression or death and a 70% reduction in the risk of death relative to chemotherapy alone.
The European Commission is expected to make a final decision on marketing authorisation by the end of this year. This follows Jemperli's recent approval in the United States and the United Kingdom for the same indication.
"If approved, dostarlimab plus chemotherapy will be the first new treatment option in decades for these patients in the European Union, offering long-awaited new hope for improved long-term outcomes," said Hesham Abdullah, GSK's head of oncology.
Read more on Proactive Investors UK
Disclaimer
Get The App
Written By: Proactive Investors
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.